FDA OKs First Cell Therapy for Severe Aplastic Anemia
The approval marks the second indication for omidubicel, following its 2023 nod for patients with hematologic malignancies set to undergo cord blood transplantation.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-oks-first-cell-therapy-severe-aplastic-anemia-2025a1000yfl?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-oks-first-cell-therapy-severe-aplastic-anemia-2025a1000yfl?src=rss
Comments
Post a Comment